Boothbay Fund Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Boothbay Fund Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-324,400	Closed	-$921K	–	1494
2024 Q1	$921K	Sell	324,400 -72,100	-18%	-$943K	0.02%	783
2023 Q4	$5.84M	Buy	396,500 +254,200	+179%	+$3.9M	0.15%	161
2023 Q3	$2.61M	Buy	+142,300	New	+$3.01M	0.06%	412
2023 Q2	–	Sell	-30,000	Closed	-$880K	–	1779
2023 Q1	$880K	Buy	+30,000	New	+$1.04M	0.02%	1051
2022 Q4	–	Sell	-44,700	Closed	-$1.26M	–	1981
2022 Q3	$1.26M	Buy	44,700 +1,000	+2%	+$24.9K	0.03%	772
2022 Q2	$842K	Buy	43,700 +13,300	+44%	+$158K	0.02%	902
2022 Q1	$391K	Buy	+30,400	New	+$687K	0.01%	1442

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Boothbay Fund Management's AMLX Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 36,060 shares worth $648K. The stake represents 0.01% of the portfolio and ranks #1347 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in AMLX as recently as Q4 2024.

Boothbay Fund Management first reported a position in AMLX in Q1 2022 and has held it in 8 quarters since. The position peaked at $3.23M in Q4 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Boothbay Fund Management held 36,060 shares of Amylyx Pharmaceuticals worth $648K as of Q2 2026.
Amylyx Pharmaceuticals was a new Boothbay Fund Management position in Q2 2026.
Amylyx Pharmaceuticals made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1347 holding.
Boothbay Fund Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 8 quarters since.
Boothbay Fund Management's Amylyx Pharmaceuticals position peaked at $3.23M in Q4 2023.
206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.